Quanterix (QTRX) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Operational performance and technology platform

• Achieved seven consecutive quarters of double-digit growth, increasing recurring revenues from 65% to 80% and expanding gross margins by 18 points while reducing cash burn by nearly half.

• Simoa platform enables ultra-sensitive detection of single molecules in blood, supporting over 3,200 publications and a 1,000-instrument install base.

• Pivoted to a service model during capital constraints, growing the accelerator business by 36% to nearly $40 million, with 70% recurring, margin-accretive orders.

• Preliminary 2024 revenue estimated at $137M, with non-GAAP gross margin guidance of 51-55% and cash burn reduced to $32M.

• Emphasized strong operational execution: double-digit revenue growth, improved gross margins, and cash flow positive target by 2026.

Strategic growth vectors and product innovation

• Three core growth vectors: expanding assay menu (especially in neurology), entering adjacencies (immunology, oncology), and advancing diagnostics.

• Launched 20 new assays in 2024 (12 neurology, 8 immunology), including brain-derived tau and a four-plex N4PD assay for neurodegeneration.

• Introduced extracellular vesicle technology and 11 new inflammatory markers, strengthening leadership in neurology and expanding Simoa utility.

• Focused on translating innovations into diagnostics, especially for Alzheimer's.

• Combined Quanterix and Akoya install base of 2,300 instruments enables immediate cross-selling and broader market reach.

Platform advancements and market expansion

• Announced Simoa One, a new platform launching by end of 2024/2025, offering order-of-magnitude sensitivity improvement, tenfold plex increase, and results in under three hours.

• Simoa One targets immunology and oncology, expanding the addressable market from $1B (neurology) to $5B.

• Utilizes code-match technology for high specificity and efficient workflow without PCR or NGS.

• Previewed launch of SIMOA One platform by end of 2025, offering up to 10x sensitivity and 10-plex capability for mid-plex segment entry.

• Positioned for leadership in ultra-sensitive biomarker detection, with over 1,000 instruments installed and 3,200+ publications.